دورية أكاديمية
The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition
العنوان: | The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition |
---|---|
المؤلفون: | Barata, Pedro C., Ornstein, Moshe C., Garcia, Jorge A. |
المصدر: | Journal of Kidney Cancer and VHL; Vol. 4 No. 2 (2017): Journal of Kidney Cancer and VHL; 10-18 ; 2203-5826 |
بيانات النشر: | Codon Publications |
سنة النشر: | 2017 |
المجموعة: | Journal of Kidney Cancer and VHL (JKCVHL) |
مصطلحات موضوعية: | Advanced renal cell carcinoma, immunotherapy, mTOR inhibitors, PD-1/PD-L1, sequential therapy, VEGF inhibitors, Kidney Cancer, Oncology |
الوصف: | Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Understanding existing data on subsequent therapies is crucial to define an optimal treatment sequence following first-line failure. This review examines the data supporting currently approved agents in this setting and provides a framework for decision-making regarding treatment sequencing beyond first-line therapy with VEGFR TKIs. |
نوع الوثيقة: | article in journal/newspaper |
وصف الملف: | application/pdf; text/html; application/xml |
اللغة: | English |
العلاقة: | https://jkcvhl.com/index.php/jkcvhl/article/view/69/160Test; https://jkcvhl.com/index.php/jkcvhl/article/view/69/161Test; https://jkcvhl.com/index.php/jkcvhl/article/view/69/170Test; https://jkcvhl.com/index.php/jkcvhl/article/view/69Test |
DOI: | 10.15586/jkcvhl.2017.69 |
الإتاحة: | https://doi.org/10.15586/jkcvhl.2017.69Test https://jkcvhl.com/index.php/jkcvhl/article/view/69Test |
حقوق: | Copyright (c) 2017 pedro barata ; https://creativecommons.org/licenses/by-nc-nd/4.0Test |
رقم الانضمام: | edsbas.65B1E4C5 |
قاعدة البيانات: | BASE |
DOI: | 10.15586/jkcvhl.2017.69 |
---|